ONLINE DATABASE SEARCH - HIV-LS-295-MEMO
1. 43307 HIV-LS-295; PUBMED-HIV-5/3/2004
Rational Design and Synthesis of Novel Dimeric Diketoacid-Containing Inhibitors of HIV-1 Integrase: Implication for Binding to Two Metal Ions on the Active Site of Integrase
Long, YQ, Jiang, XH, Dayam, R, Sanchez, T, Shoemaker, R, Sei, S, and Neamati, N
J Med Chem 2004. 47(10): 2561-2573
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15115398&dopt=abstract
2. 43308 HIV-LS-295; SCIFINDER-HIV-4/27/2004
The Reverse Transcriptase (RT) Mutation V118I is Associated with Virologic Failure on Abacavir-based Antiretroviral Treatment (ART) in HIV-1 Infection
Saeberg, Paer, Koppel, Kristina, Bratt, Goeran, Fredriksson, Eva Lena, Hejdeman, Bo, Sitbon, Gisela, and Sandstroem, Eric
Scandinavian Journal of Infectious Diseases 2004. 36(1): 40-45
3. 43309 HIV-LS-295; PUBMED-HIV-5/3/2004
An unusual "senseless" 2',5'-oligoribonucleotide with potent anti-HIV activity
Aboul-Fadl, T, Agrawal, VK, Buckheit, RW Jr, and Broom, AD
Nucleosides Nucleotides Nucleic Acids 2004. 23(3): 545-54
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15113022&dopt=abstract
4. 43310 HIV-LS-295; PUBMED-HIV-5/3/2004
Design, synthesis and evaluation of potential inhibitors of HIV gp120-CD4 interactions
Boussard, C, Klimkait, T, Mahmood, N, Pritchard, M, and Gilbert, IH
Bioorg Med Chem Lett 2004. 14(10): 2673-6
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15109676&dopt=abstract
5. 43311 HIV-LS-295; PUBMED-HIV-5/3/2004
Bis-Anthracycline Antibiotics Inhibit Human Immunodeficiency Virus Type 1 Transcription
Kutsch, O, Levy, DN, Bates, PJ, Decker, J, Kosloff, BR, Shaw, GM, Priebe, W, and Benveniste, EN
Antimicrob Agents Chemother 2004. 48(5): 1652-1663
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15105117&dopt=abstract
6. 43312 HIV-LS-295; PUBMED-HIV-5/3/2004
Novel 4'-Substituted Stavudine Analog with Improved Anti-Human Immunodeficiency Virus Activity and Decreased Cytotoxicity
Dutschman, GE, Grill, SP, Gullen, EA, Haraguchi, K, Takeda, S, Tanaka, H, Baba, M, and Cheng, YC
Antimicrob Agents Chemother 2004. 48(5): 1640-1646
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15105115&dopt=abstract
7. 43313 HIV-LS-295; PUBMED-HIV-5/3/2004
Effects of Drug Resistance Mutations L100I and V106A on the Binding of Pyrrolobenzoxazepinone Nonnucleoside Inhibitors to the Human Immunodeficiency Virus Type 1 Reverse Transcriptase Catalytic Complex
Locatelli, GA, Campiani, G, Cancio, R, Morelli, E, Ramunno, A, Gemma, S, Hubscher, U, Spadari, S, and Maga, G
Antimicrob Agents Chemother 2004. 48(5): 1570-1580
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15105107&dopt=abstract
8. 43314 HIV-LS-295; SCIFINDER-HIV-4/27/2004
Synergistic attachment inhibitor-fusion inhibitor compositions for the prevention and treatment of acquired immunodeficiency syndrome((Tanox, Inc. USA)
Fung, Sek Chung
PATENT: WO 2004028473 A2; ISSUE DATE: 20040408
APPLICATION: 2003; PP: 22 pp.
9. 43315 HIV-LS-295; SCIFINDER-HIV-4/27/2004
Treatment of viral diseases by 1,3,5-triazine nucleoside and nucleotide analogs, and preparation thereof ((Koronis Pharmaceuticals, Incorporated USA)
Daifuku, Richard, Gall, Alexander, and Sergueev, Dmitri
PATENT: WO 2004028454 A2; ISSUE DATE: 20040408
APPLICATION: 2003; PP: 108 pp.
10. 43316 HIV-LS-295; PUBMED-HIV-5/3/2004
Tipranavir: the first nonpeptidic protease inhibitor
Cheonis, N
BETA 2004. 16(2): 15-7
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15104065&dopt=abstract
11. 43317 HIV-LS-295; SCIFINDER-HIV-4/27/2004
Preparation and pharmaceutical compositions of indole, azaindole and related heterocyclic 4-alkenyl piperidine amides ((USA))
Wang, Tao, Kadow, John F, Meanwell, Nicholas A, Yeung, Kap-Sun, Zhang, Zhongxing, Yin, Zhiwei, Qiu, Zhilei, Deon, Daniel H, James, Clint A, Ruediger, Edward H, and Bachand, Carol
PATENT: US 20040063744 A1; ISSUE DATE: 20040401
APPLICATION: 2003-32154; PP: 181 pp.
12. 43318 HIV-LS-295; PUBMED-HIV-5/3/2004
A 14-Day Dose-Response Study of the Efficacy, Safety, and Pharmacokinetics of the Nonpeptidic Protease Inhibitor Tipranavir in Treatment-Naive HIV-1-Infected Patients
McCallister, S, Valdez, H, Curry, K, MacGregor, T, Borin, M, Freimuth, W, Wang, Y, and Mayers, DL
J Acquir Immune Defic Syndr 2004. 35(4): 376-382
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15097154&dopt=abstract
13. 43319 HIV-LS-295; SCIFINDER-HIV-4/27/2004
Cellular protein Inip76, its presence in HIV-1 integrase protein complex, role in retroviral integration, and use as drug target((K U Leuven Research & Development, Belg.)
Cherepanov, Peter, Debyser, Zeger, and De Clercq, Erik
PATENT: GB 2393440 A1; ISSUE DATE: 20040331
APPLICATION: 2002-22361; PP: 50 pp.
14. 43320 HIV-LS-295; PUBMED-HIV-5/3/2004
Pharmacokinetic Evaluation and Short-Term Activity of Stavudine, Nevirapine, and Nelfinavir Therapy in HIV-1-Infected Adults
Skowron, G, Leoung, G, Hall, DB, Robinson, P, Lewis, R, Grosso, R, Jacobs, M, Kerr, B, MacGregor, T, Stevens, M, Fisher, A, Odgen, R, and Yen-Lieberman, B
J Acquir Immune Defic Syndr 2004. 35(4): 351-358
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15097151&dopt=abstract
15. 43321 HIV-LS-295; SCIFINDER-HIV-4/27/2004
TAT-gp120 interaction-based mechanism for HIV-1 entry into host cells, and peptides inhibiting this mechanism ((Creabilis Therapeutics S.R.L., Italy)
Bussolino, Federico and Marchio, Serena
PATENT: WO 2004024173 A2; ISSUE DATE: 20040325
APPLICATION: 2003; PP: 87 pp.
16. 43322 HIV-LS-295; SCIFINDER-HIV-4/27/2004
Mutational profiles in HIV-1 protease correlated with phenotypic drug resistance((Tibotec Pharmaceuticals Ltd., Ire.)
De Meyer, Sandra, Azijn, Hilde, and De Bethune, Marie-pierre TMMG
PATENT: WO 2004003817 A1; ISSUE DATE: 20040108
APPLICATION: 2003; PP: 32 pp.
17. 43323 HIV-LS-295; PUBMED-HIV-5/3/2004
Phase II trial of infusional cyclophosphamide, doxorubicin, and etoposide in patients with HIV-associated non-Hodgkin's lymphoma: an Eastern Cooperative Oncology Group Trial (E1494)
Sparano, JA, Lee, S, Chen, MG, Nazeer, T, Einzig, A, Ambinder, RF, Henry, DH, Manalo, J, Li, T, and Von, Roenn JH
J Clin Oncol 2004. 22(8): 1491-500
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15084622&dopt=abstract
18. 43324 HIV-LS-295; PUBMED-HIV-5/3/2004
Novel halogenated nitrobenzylthioinosine analogs as es nucleoside transporter inhibitors
Gupte, A and Buolamwini, JK
Bioorg Med Chem Lett 2004. 14(9): 2257-60
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15081020&dopt=abstract
19. 43325 HIV-LS-295; PUBMED-HIV-5/3/2004
Measurement of anti-HIV activity of marketed vaginal products and excipients using a PBMC-based in vitro assay
Rohan, LC, Ratner, D, McCullough, K, Hiller, SL, and Gupta, P
Sex Transm Dis 2004. 31(3): 143-8
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15076925&dopt=abstract
20. 43326 HIV-LS-295; SCIFINDER-HIV-4/27/2004
The human immunodeficiency virus type 1 ribosomal frameshifting site is an invariant sequence determinant and an important target for antiviral therapy
Biswas, Preetha, Jiang, Xi, Pacchia, Annmarie L, Dougherty, Joseph P, and Peltz, Stuart W
Journal of Virology 2004. 78(4): 2082-2087
21. 43327 HIV-LS-295; PUBMED-HIV-5/3/2004
Synthesis and biological evaluation of novel tert-azido or tert-amino substituted penciclovir analogs
Ok, Kim H, Won, Baek H, Ryong, Moon H, Kim, DK, Woo, Chun M, and Shin, Jeong L
Org Biomol Chem 2004. 2(8): 1164-8
HYPERLINK: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&list_uids=15064793&dopt=abstract
22. 43328 HIV-LS-295; SCIFINDER-HIV-4/27/2004
Polymer conjugates with HIV gp41-derived peptides and their therapeutic use((Trimeris, Inc. USA)
Bray, Brian, Kang, Myung-Chol, Tvermoes, Nicolai, Kinder, Daniel, and Lackey, John William
PATENT: WO 2004029073 A2; ISSUE DATE: 20040408
APPLICATION: 2003; PP: 79 pp.
23. 43329 HIV-LS-295; WOS-HIV-4/25/2004
Synthesis and anti HIV-1 activity of 2-[[2-(3,5-dimethylphenoxy)ethyl]thio]pyrimidin4(3 H)-ones
Novikov, MS, Ozerov, AA, Sim, OG, and Buckheit, RW
KHIM GETEROTSIKL+ 2004(1): 42-47
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220011500005
24. 43330 HIV-LS-295; WOS-HIV-4/25/2004
Design, synthesis and preliminary evaluation of peptidomimetic inhibitors of HIV aspartic protease with an epoxyalcohol core
Benedetti, F, Berti, F, Miertus, S, Romeo, D, Schillani, F, and Tossi, A
ARKIVOC 2003: 140-154
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220561500013
25. 43331 HIV-LS-295; WOS-HIV-4/25/2004
Synthesis of the 5 '-phosphonate of 4(S)-(6-amino-9H-purin-9-yl)tetrahy ro-2(S)-furanmethanol [S,S-IsoddA]
Nair, V and Sharma, PK
ARKIVOC 2003: 10-14
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220561700002
26. 43332 HIV-LS-295; WOS-HIV-5/2/2004
Pharmacokinetic characteristics of ritonavir, zidovudine, lamivudine, and stavudine in children with human immunodeficiency virus infection
Fletcher, CV, Yogev, R, Nachman, SA, Wiznia, A, Pelton, S, McIntosh, K, and Stanley, K
PHARMACOTHERAPY 2004. 24(4): 453-459
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220624600004
27. 43333 HIV-LS-295; WOS-HIV-5/2/2004
Orally bioavailable competitive CCR5 antagonists
Thoma, G, Nuninger, F, Schaefer, M, Akyel, KG, Albert, R, Beerli, C, Bruns, C, Francotte, E, Luyten, M, MacKenzie, D, Oberer, L, Streiff, MB, Wagner, T, Walter, H, Weckbecker, G, and Zerwes, HG
J MED CHEM 2004. 47(8): 1939-1955
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220642100010
28. 43334 HIV-LS-295; WOS-HIV-5/2/2004
Selective inhibition of HIV-1 reverse transcriptase (HIV-1 RT) RNase H by small RNA hairpins and dumbbells
Hannoush, RN, Carriero, S, Min, KL, and Damha, MJ
CHEMBIOCHEM 2004. 5(4): 527-533
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220773500016
29. 43335 HIV-LS-295; WOS-HIV-5/2/2004
On the role of interferon regulatory factors in HIV-1 replication
Marsili, G, Borsetti, A, Sgarbanti, M, Remoli, AL, Ridolfi, B, Stellacci, E, Ensoli, B, and Battistini, A
ANN NY ACAD SCI 2003. 1010: 29-42
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000189446300005
30. 43336 HIV-LS-295; WOS-HIV-5/2/2004
Six-year follow-up of HIV-1-infected adults in a clinical trial of antiretroviral therapy with indinavir, zidovudine, and lamivudine
Gulick, RM, Meibohm, A, Havlir, D, Eron, JJ, Mosley, A, Chodakewitz, JA, Isaacs, R, Gonzalez, C, McMahon, D, Richman, DD, Robertson, M, and Mellors, JW
AIDS 2003. 17(16): 2345-2349
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220672200009
31. 43337 HIV-LS-295; WOS-HIV-5/2/2004
Resistance of HIV-1 to multiple antiretroviral drugs in France: a 6-year survey (1997-2002) based on an analysis of over 7000 genotypes
Tamalet, C, Fantini, J, Tourres, C, and Yahi, N
AIDS 2003. 17(16): 2383-2388
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220672200014
32. 43338 HIV-LS-295; WOS-HIV-5/2/2004
An open-label assessment of TMC 125-a new, next-generation NNRTI, for 7 days in HIV-1 infected individuals with NNRT1 resistance
Gazzard, BG, Pozniak, AL, Rosenbaum, W, Yeni, GP, Staszewski, S, Arasteh, K, De, Dier K, Peeters, M, Woodfall, B, Stebbing, J, and Vant', Klooster GAE
AIDS 2003. 17(18): F49-F54
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220672800001
33. 43339 HIV-LS-295; WOS-HIV-5/2/2004
HIV biological variability unveiled: frequent isolations and chimeric receptors reveal unprecedented variation of coreceptor use
Karlsson, I, Antonsson, L, Shi, Y, Karlsson, A, Albert, J, Leitner, T, Olde, B, Owman, C, and Fenyo, EM
AIDS 2003. 17(18): 2561-2569
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220672800003
34. 43340 HIV-LS-295; WOS-HIV-5/2/2004
Molecular mapping of epitopes for interaction of HIV-1 as well as natural ligands with the chemokine receptors, CCR5 and CXCR4
Antonsson, L, Boketoft, A, Garzino-Demo, A, Olde, B, and Owman, C
AIDS 2003. 17(18): 2571-2579
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220672800004
35. 43341 HIV-LS-295; WOS-HIV-5/2/2004
Clinical and immunological impact of HIV envelope V3 sequence variation after starting initial triple antiretroviral therapy
Brumme, ZL, Dong, WWY, Yip, B, Wynhoven, B, Hoffman, NG, Swanstrom, R, Jensen, MA, Mullins, JI, Hogg, RS, Montaner, JSG, and Harrigan, PR
AIDS 2004. 18(4): F1-F9
HYPERLINK: http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220647400001
36. 43342 HIV-LS-295; WOS-HIV-5/2/2004
Evaluation of nevirapine and/or hydroxyurea with nucleoside reverse transcriptase inhibitors in treatment-naive HIV-1-infected subjects
Blanckenberg, DH, Wood, R, Horban, A, Beniowski, M, Boron-Kaczmarska, A, Trocha, H, Halota, W, Schmidt, RE, Fatkenheuer, G, Jessen, H, and Lange, JMA
AIDS 2004. 18(4): 631-640
HYPERLINK:
http://publishorperish.nih.gov/isicgi/gateway/Gateway.cgi?KeyUT=000220647400007